Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, Mizoguchi J, Kato K
Drug Safety Research Laboratories, Takeda Chemical Industries, Ltd, Osaka, Japan.
Growth Factors. 1993;9(1):73-80. doi: 10.3109/08977199308991583.
Intravenous administration of human basic fibroblast growth factor (bFGF) for 2 weeks stimulated osteoblast proliferation and new bone formation in various skeletal bones in young and aged rats at dosage levels of 0.1 mg/kg/day and greater. Morphometry of the soft X-ray radiograms of cross sections of the tibia indicated about a 20% increase in the calcified bone area of the diaphysis at 0.1 mg/kg/day. The Ca and hydroxyproline contents showed statistically significant increases at this dosage. The new bone formation was found only on the endosteal side, and no periosteal bone formation was found. Similar systemic osteogenic potential was seen after intravenous administration of other growth factors of the FGF family, human acidic FGF and human heparin-binding secretory transforming protein-1. The above results suggest a potential therapeutic role for these growth factors in bone-loss diseases such as osteoporosis.
以0.1mg/kg/天及更高剂量水平,对年轻和老年大鼠静脉注射人碱性成纤维细胞生长因子(bFGF)2周,可刺激各骨骼中的成骨细胞增殖和新骨形成。胫骨横断面软X线照片的形态测量显示,在0.1mg/kg/天剂量下,骨干钙化骨面积增加约20%。在此剂量下,钙和羟脯氨酸含量有统计学意义的增加。新骨形成仅见于骨内膜侧,未见骨膜骨形成。静脉注射FGF家族的其他生长因子,人酸性FGF和人肝素结合分泌转化蛋白-1后,也观察到类似的全身成骨潜能。上述结果表明这些生长因子在骨质疏松症等骨质流失疾病中具有潜在的治疗作用。